title-img

The Truth Is In...

Who ever said, “vino veritas” (in wine, there is truth), hasn’t written enough. I say, “in writing veritas.”   MarketWatch asked me to write an article about one’s investment strategy in the interest rate environment on the horizon.  When I first sat down to write, I thought that I was a bit neutral on the direction of interest rates. However, by the time I finished (as you’ll see), it was painfully obvious that interest rates are more likely to go down than up. It’s a story of global prosperity that has been in part prepped up by finite sources (mostly debt).

I would not bet my career or even a bottle of fine beer (Fat Tire – those in Colorado will know), but there are too many “uncertainties” on the horizon for higher interest rates.  In the article, I offered two stocks, Glaxosmithkline (GSK) and Johnson & Johnson (JNJ)  that should do well in any interest rate environment.

Vitaliy Katsenelson

I am the CEO at Investment Management Associates, which is anything but your average investment firm. (Seriously, take a look.)

I wrote two books on investing, which were published by John Wiley & Sons and have been translated into eight languages. (Even in Polish!)

In a brief moment of senility, Forbes magazine called me “the new Benjamin Graham.” (They must have been impressed by the eloquence of the Polish translation.)

Don't miss new articles

We'll let you know when we publish new articles





YOU MIGHT ALSO LIKE: